Daily Medication Pearl: Mitomycin (Jelmyto)

Article

Jelmyto is an alkylating drug indicated for the treatment of adult patients with low-grade upper tract urothelial cancer.

Medication Pearl of the Day: Mitomycin (Jelmyto)

Indication: Jelmyto is an alkylating drug indicated for the treatment of adult patients with low-grade upper tract urothelial cancer.

Insight:

  • Dosing: Administer 1.3 g of sodium bicarbonate orally the evening prior to, the morning of, and 30 minutes prior to instillation procedure.
  • Dosage forms: Two 40 mg (each) single-dose vials of mitomycin for pyelocalyceal solution.
  • Adverse events: The most common adverse reactions (≥ 20%) are ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, fatigue, nausea, abdominal pain, dysuria, and vomiting.
  • Mechanism of action: Mitomycin inhibits the synthesis of DNA. The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
  • Manufacturer: UroGen Pharma

Source: LABEL (fda.gov)

Related Videos
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room - Image credit: pressmaster | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
cancer pain management | Image Credits: © Burlingham - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign | stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.